Title of article :
Olfactory Neuroblastoma: A 15Year Single Institution Experience
Author/Authors :
Khademi، Bijan نويسنده Khalili Hospital, Shiraz Institute for Cancer Research,Department of Otolaryngology,Shiraz University of Medical Sciences,Shiraz,Iran , , Safari، Sima نويسنده Khalili Hospital, Student Research Committee,Department of Otolaryngology, and Head and Neck Surgery,Shiraz University of Medical Sciences,Shiraz,Iran , , Hosseini، Sare نويسنده Cancer Research Center, School of Medicine,Department of Radiation Oncology,Mashhad University of Medical Sciences,Mashhad,Iran , , Mohammadianpanah، Mohammad نويسنده Colorectal Research Center,Shiraz University of Medical Sciences,Shiraz,Iran ,
Issue Information :
فصلنامه با شماره پیاپی سال 2015
Pages :
5
From page :
1
To page :
5
Abstract :
Background: Olfactory neuroblastoma or esthesioneuroblastoma is a rare malignant neoplasm of the olfactory neuroepithelium. Objectives: This study aimed to investigate the clinical presentation, characteristics and treatment outcome of fourteen patients with olfactory neuroblastoma. Patients and Methods: This retrospective study reviewed and analyzed 14 patients with olfactory neuroblastoma during the last 15 years at two referral tertiary academic hospitals of Shiraz University of Medical Sciences. Patients under 16 years old were excluded from the study. Kadish classification was used for staging the tumors. In addition, the tumors were histopathologically graded according to Hyams’ grading classification. Results: There were 6women(43%) and 8men(57%) ranging from 16 to 56 years old, with a median age of 40 years at diagnosis. Nasal obstruction (93%), facial or sinus pain (57%), and nasal bleeding (43%) were the most frequent presentation. Two patients (14%) had stage A, 3 (21.5%) had stage B, 6 (43%) had stage C, and 3 (21.5%) had stageDdisease. After initial treatment, five patients developed local and/or distant recurrent disease. After a median follow-up of 73 (range 14 - 108) months for surviving patients, 10 patients (71.5%) were alive and without disease, one (7%) was alive with disease, and 3 (21.5%) died due to the disease. The 5-year disease-free and overall survival rates were 71.4% and 75.7%, respectively. Conclusions: At our center, patients with olfactory neuroblastoma tend to present at advanced stages; therefore, combined local treatment and incorporation of chemotherapy may improve outcome.
Keywords :
surgery , radiotherapy , chemotherapy , Olfactory neuroblastoma , Esthesioneuroblastoma
Journal title :
Reports of Radiotherapy and Oncology
Journal title :
Reports of Radiotherapy and Oncology
Record number :
2400981
Link To Document :
بازگشت